drugset / Trial / NCT05777109
Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
RandomizedParallel-groupDouble-blindPrevention
Summary
A Dual-center , Randomized, double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults
Timeline
- Start
- 2023-04-20
- Primary completion
- 2024-04-05
- Completion
- 2024-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | HS-20090 | Monoclonal antibody | 120 mg | Subcutaneous |
Indications
No indication recorded.